Sept. 26, 2025 -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into an agreement to acquire Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. The closing of this acquisition is subject to customary closing conditions, including approval by Melt stockholders,

Numab to receive first milestone payment Boehringer Ingelheim has advanced its novel tumor antigen targeting T cell engager resulting from a collaboration with Numab into preclinical development Sept. 25, 2025 -- Numab Therapeutics AG (“Numab”), a biotechnology company advancing a proprietary pipeline of multi-specific antibodies in immunology and oncology, announced today that Boehringer Ingelheim has advanced its novel T cell engager for the treatment of lung and gastrointestinal (GI) cancer

Sept. 25, 2025 -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is pleased to announce that it has signed a distribution agreement with Veridion Group (“Veridion”) of New Zealand, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market. “With the approval of the first Authorized Prescriber

Sept. 24, 2025 -- Cellectar Biosciences, Inc. (“Cellectar”) (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and Evestia Clinical (“Evestia”), a leading independent global specialist Contract Research Organization (CRO), have entered into an agreement whereby Evestia will provide Cellectar with full CRO services for their upcoming Phase 1b study evaluating CLR 125 for the treatment of triple-negative b

Sept. 22, 2025 -- FOXO Technologies Inc. (OTCID: FOXO) (“FOXO” or the “Company”), announces the closing of the acquisition of Vector Biosource Inc. (“Vector”). Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 ($0.9 million on an annual run rate basis) and is expected to grow significantly post-acquisition. The purchase

Sept. 22, 2025 -- Starpharma , an innovative Australian biotechnology company, today announced the signing of a collaboration and license agreement with Genentech, a member of the Roche Group, to develop potential cancer therapies that leverage Starpharma’s proprietary DEP® drug delivery technology. Starpharma will receive an upfront payment of USD $5.5 million (~AUD $8.3 million), and is eligible for development, commercial, and net sales milestones of up to USD $564 million (~AUD $855 millio

– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total equity value of up to approximately $3.5 billion – – Transaction reflects pegozafermin’s potential best-in-disease profile for the treatment of moderate to severe metabolic dysfunction-associated steatohepatitis (MASH) – – 89bio to join the Roche Grou

Sept. 17, 2025 -- XOMA Royalty Corporation (NASDAQ: XOMA) (“XOMA Royalty” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of HilleVax, Inc. (NASDAQ: HLVX) (“HilleVax”) common stock for a price per share of $1.95 in cash (the “Cash Amount”), plus one non-tradeable

Sept. 16, 2025 -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis. Under the terms of the amended agreement, Exelixis will utilize Adagene’s SAFEbody technology platform to generate a masked monoclonal antibody from the company’s pipeline for the development of an antibody-drug conjugate (ADC) against an Exelixis-nominated solid tumor target. Adagene is eligible to receive development and commercialization mile

September 16, 2025 – Italfarmaco S.p.A. today announced an exclusive agreement with Multicare Pharma, a prominent pharmaceutical company in Latin America. Multicare Pharma will support the regulatory approval in Brazil and distribute givinostat (Duvyzat®), Italfarmaco’s novel histone deacetylase (HDAC) inhibitor to treat Duchenne muscular dystrophy (DMD). According to the terms of the agreement, Multicare will manage supply and distribution operations for the drug within Brazil. No financial ter